Kornimate/medical-research-clean huggingface dataset:
plasma adsorption in patients with confirmed covid-19

Conditions: Respiratory Failure; ARDS

Summary: to characterize the ability of the d2000 cartridge in combination with the optia spd protocol to reduce the morbidity and mortality associated with sars-cov-2 infection in patients admitted to the icu.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * admitted to icu * diagnosis of sars-cov-2 with any one of the following conditions: 1. early acute lung injury (ali)/early acute respiratory distress syndrome (ards); or 2. severe disease, defined as: 1. dyspnea, 2. respiratory frequency ≥ 30/min 3. blood oxygen saturation ≤ 93% 4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or 5. lung infiltrates \> 50% within 24 to 48 hours; or 3. life-threatening disease, defined as: 1. respiratory failure, 2. septic shock, and/or 3. multiple organ dysfunction or failure. * patient fact sheet is provided to the subject. * subject or legal representative is able and willing to give informed consent. if authorized by the irb, emergent plasma adsorption with the d2000 cartridge may be initiated prior to consent. exclusion criteria: * treatment limitation or a do not attempt to resuscitate in place * pregnancy * significant or uncontrolled bleeding * in the opinion of the investigator, any other condition that precludes plasma adsorption with the d2000

Keywords: sars-cov-2 covid-19 spectra optia apheresis system d2000 cartridge terumo bct marker therapeutics
social and cognitive factors in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Carpal Tunnel

Summary: carpal tunnel syndrome (cts) is a compressive peripheral neuropathy, characterized by pain, tingling sensation and paresthesia in the territory of the median nerve, symptoms modulated by psychosocial factors (eg, catastrophic thinking, depression, anxiety). the objective of the study is to determine those psychological and social components that influence the symptoms and function of patients with cts. an observational cross-sectional design will be performed in patients with cts. the patients will be selected consecutively in two hospitals of the south east metropolitan health service (santiago, chile). the study variables will include: perception of pain using the visual analogue scale (vas), the extent of symptoms will be evaluated using the katz diagram; functional assessment using the abbreviated version of the disabilities of the arm, shoulder and hand questionnaire (quickdash); catastrophic thinking as a response to pain using the pain catastrophizing scale (pcs), fear of movement using the tampa scale for kinesiophobia (tsk-11), and emotional state was assessed using the hospital anxiety and depression scale (hads). both are valid and reliable measures used to evaluate the influence of psychosocial factors in patients with cts. individual subject factors including duration of symptoms, type of work (desk / non-desk), bmi, age, gender, educational level and economic income will be collected through an interview process.


Eligibility criteria:
inclusion criteria: * over 18 years of age, moderate or severe cts medical diagnosis, duration of symptoms for more than three months, acceptance to participate in the study. exclusion criteria: * inability to understand instructions, non-controlled mental health pathology, cognitive problems, and previous surgery in the upper limb.

Keywords: chronic pain disability psychosocial factors social determinants of health
olpasiran trials of cardiovascular events and lipoprotein(a) reduction (ocean(a)) - outcomes trial

Conditions: Atherosclerotic Cardiovascular Disease

Summary: the primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (chd death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ascvd) and elevated lipoprotein(a).


Eligibility criteria:
inclusion criteria: * age 18 to ≤ 85 years * lp(a)≥ 200 nmol/l during screening * history of ascvd as evidenced by history of either: * myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or * coronary revascularization with percutaneous coronary intervention and at least 1 additional risk factor. exclusion criteria: * severe renal dysfunction * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 3 x upper limit of normal (uln), or total bilirubin (tbl) \> 2 x uln during screening * history of hemorrhagic stroke * history of major bleeding disorder * planned cardiac surgery or arterial revascularization * severe heart failure * current, recent, or planned lipoprotein apheresis * previously received ribonucleic acid therapy specifically targeting lp(a)

Keywords: atherosclerotic cardiovascular disease ascvd amg 890 olpasiran
cisplatin, pemetrexed and bevacizumab for untreated malignant mesothelioma

Conditions: Mesothelioma

Summary: to estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab

secondary endpoints will include: objective response rate overall survival in addition, the objective of the analysis of the correlative science data is to determine any association between tumor expression of vegf/kdr complex and/or the presence of sv40 (as detected by pcr amplification) and objective response.

Eligibility criteria:
inclusion criteria 5.2.1 patients must have histologically proven malignant mesothelioma (epithelial, sarcomatoid, or mixed subtype) not amenable to curative surgery or radiotherapy. eligible sites of origin include the pleura, peritoneum, and tunica vaginalis. 5.2.2 patient's disease must not be amenable to curative treatment with surgery. evidence of gross unresectability will include but not be limited to direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology. 5.2.3 patients must be \> 18 years old 5.2.4 patients must have measurable disease. adequate organ function and functional status exclusion criteria: a. general medical concerns 5.3.1 patients must not be pregnant or breast feeding. 5.3.2 no "currently active" second malignancy other than non-melanoma skin cancer. patients are not considered to have a "currently active" second malignancy if they have completed therapy and have a less than 30% risk of relapse. 5.3.3 no uncontrolled intercurrent illness including but not limited to: active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social situations that would limit compliance with study requirements. 5.3.4 no hiv positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with study medications. 5.3.5 history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in the study. 5.3.6 inability to interrupt aspirin or other non-steroidal medication for a 5 day period. c. bevacizumab-specific concerns subjects meeting any of the following criteria are ineligible for study entry: 5.3.7 patients with brain metastases are excluded 5.3.8 history of myocardial infarction or cva (stroke) within 6 months of study entry. 5.3.9 evidence of bleeding diathesis or coagulopathy. patients on therapeutic doses of coumadin are eligible as long as the inr is maintained in the range of 2-3 and there is no evidence of active bleeding. 5.3.10 major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study 5.3.11 urine protein:creatinine ratio less than 1.0 at screening 5.3.12 serious, non-healing wound, ulcer, or bone fracture

Keywords: mesothelioma bevacizumab chemotherapy
a prospective study to evaluate the correlation between oculometric measurements and clinical endpoints in pd patients

Conditions: Idiopathic Parkinson Disease

Summary: this is a prospective study in a cohort of about 500 patients with idiopathic parkinson's disease, examined routinely in the neurological outpatient clinic. this study aims to evaluate the correlation between oculometric measures and clinical endpoints. subjects will be evaluated following a physician examination.the evaluations will include mds-updrs examination, as well as an oculometric evaluation for eye movements. in addition, 500 healthy subjects will be evaluated.

this is a prospective study in a cohort of patients with idiopathic pd who are visiting the parkinson's outpatient clinic. the aim of the study is to evaluate the correlation between oculometric measures and mds-updrs score in subjects who meet the inclusion criteria and who provide a signed informed consent. this study is designed to evaluate the correlation between oculometric measures and the movement disorder society-sponsored revision of the unified parkinson's disease rating scale (mds-updrs). subjects will be evaluated at their visit to the clinic. the evaluations will include an mds-updrs examination by a certified neurologist and other tests. in addition, all patients will undergo a neuralight session for oculometric evaluation along with eye-tracking recordings. all assessments will be performed during a clinic visit unless authorized to be conducted remotely. in addition, 500 healthy subjects will be evaluated, undergoing a neuralight session for oculometric evaluation along with eye-tracking recordings.

Eligibility criteria:
pd patients: inclusion criteria: * men and women with idiopathic pd (hoehn \& yahr scale 1-5) * age between 18 and 85 years old * normal or corrected vision * ability to follow instructions * willing and able to sign an informed consent form exclusion criteria: * inability to sit for 20 minutes on a chair in a calm manner * personal or 1st degree relative history of epilepsy * additional neurological diseases * drug or alcohol abuse healthy subjects: inclusion criteria: * age between 18 and 85 years old * normal or corrected vision * ability to follow instructions * willing and able to sign an informed consent form exclusion criteria * inability to sit for 20 minutes on a chair in a calm manner * personal or 1st degree relative history of epilepsy * neurological diseases * drug or alcohol abuse
safety and efficacy of drug-coated balloon for de-novo lesions in patients with acute coronary syndromes (dcb-acs)

Conditions: Drug-Coated Balloon; De Novo Stenosis; Acute Coronary Syndromes; ACS; DCB; Clinical Trial; Coronary Artery Disease

Summary: the dcb-acs trial is a prospective, multi-center, non-inferiority, randomized controlled trail. the purpose of this trial is to evaluate the safety and efficacy of drug-coated balloon(dcb) in de novo lesions for acute coronary syndromes (acs) .

patients with acs and indications for percutaneous coronary intervention were randomly assigned (1:1) to receive angioplasty with dcb or implantation of a zotarolimus-eluting coronary stent(zes) . dual anti-platelet therapy was given according to current guidelines. follow-up was originally scheduled at by telephone or clinical visit at 1 month, 6 months, 12 months, and 24 months after discharge, and coronary angiography and ffr measurements will be carried out at 9 months.the primary objective is to show non-inferiority of dcb versus drug-eluting stent(des) regarding the functional assessment of target lesion by ffr at 9 months.

Eligibility criteria:
inclusion criteria: 1. age≥18 years and \<80 years; 2. acs patients eligible for percutaneous coronary intervention; 3. successful preparation is defined as ≤ 30% residual stenosis with thrombolysis in myocardial infarction (timi) grade iii flow and not evidence of type c-f dissection; 4. vessel diameter from 2.25mm-4.0 mm ; 5. lesion length ≤ 28 mm; 6. a single culprit lesion or 1 lesion in each of two vessels ; 7. eligible for enrollment and provide written informed consent. exclusion criteria: clinical exclusion criteria： 1. stable angina or asymptomatic myocardial ischemia; 2. cardiogenic shock or requiring mechanical support for breathing and circulation; 3. hemodynamically unstable tachyarrhythmia or bradyarrhythmia; 4. plan to perform cardiac surgery or non-cardiac surgery within 24 months of percutaneous coronary intervention; 5. a history of stroke within 6 months; 6. history of severe renal insufficiency; 7. life expectancy \< 12 months; 8. pregnant women; 9. allergies to aspirin, clopidogrel, ticagrelor, heparin, contrast agents, and paclitaxel, patients with systemic lupus erythematosus or other systemic immune diseases; 10. patients not suitable for enrollment considered by researcher; 11. currently participating in another trial before reaching the primary endpoint; 12. inability to provide informed consent. image exclusion criteria 1. chronic total occlusion (cto); 2. left main lesion; 3. bifurcation lesions treated with double stents; 4. moderate to severe distortion, angulation or severe calcification lesions; 5. coronary artery graft stenosis; 6. in-stent restenosis; 7. to be re-hospitalized for the other scheduled pci treatment; 8. myocardial bridge at the target lesion.

Keywords: drug-coated balloon de-novo lesions acute coronary syndromes dcb-acs acs dcb clinical trial coronary artery disease
"right ventricular outflow tract posterior septum pacing" in predicting ventricular outflow tract ventricular tachycardia origin

Conditions: Ventricular Outflow Tract Ventricular Arrhythmias; Radio Frequency Catheter Ablation

Summary: the goal of this clinical trial is to make clear that a new method, right ventricular outflow tract (rvot) posterior septum pacing, has a greater accuracy in predicting the origin of ventricular outflow tract (vot) ventricular arrhythmias (vas) compared to the previous electrocardiographic standards for the identification of the origin of ventricular outflow tract. the secondary aim is to investigate, by using the new method, if it can optimize the procedure of radiofrequency catheter ablation. researches will break the method of this investigation into two steps: first step have enrolled 100 patients. this step would be used to compare the results predicted by right ventricular outflow tract posterior septum pacing, with the previously used electrocardiographic criteria and actual target site. the second step will enroll another 100 patients. in this step, patients will be divided into two groups, one being the new protocol group and the other being the convention group. patients will also be followed up, for 1 month and 3 months at outpatient clinic post procedure. procedure time, success rate, fluoroscopy exposure time and complications, are compared between rvot posterior septum pacing group and convention group.


Eligibility criteria:
inclusion criteria: * sign informed consent form * age more than 18 years old * able to understand the purpose of the experiment, voluntarily participate, willing to complete follow-up according to the requirement of the experimental protocol. exclusion criteria: * severe cardiopulmonary, liver and kidney dysfunction, and inability to tolerate surgery due to coagulation dysfunction * viral myocarditis, myocardial infarction or stroke with a course of less than six months * simultaneously accompanied by malignant tumours, with an expected lifespan of less than or equal to 1 year * severe thoracic deformity * advanced age (more than 90 years old) * other situations that the researcher deems unsuitable for participation in the study
dietary anthocyanins improve lipid metabolism in a dose - dependent manner

Conditions: Dyslipidemias

Summary: in order to study the effect of anthocyanins on the improvement of glucose and lipid metabolism, randomized intervention trials were conducted to compare the effects of anthocyanins on the improvement of glucose and lipid metabolism in different dose groups.to explore the best dose of anthocyanins for the prevention and treatment of anthocyanin metabolic diseases provide an important scientific basis.

in order to study the effect of anthocyanins on the improvement of glucose and lipid metabolism, randomized controlled trials were conducted to enrolled 300 patients with dyslipidemia. the subjects were divided into 0 mg / d, 40 mg / d, 80 mg / d, 320 mg/ d five dose groups, intervention for 12 weeks, comparing different doses of anthocyanins on glucose and lipid metabolism.to explore the best dose of anthocyanins for the prevention and treatment of anthocyanin metabolic diseases provide an important scientific basis.

Eligibility criteria:
inclusion criteria: * dyslipidemia * subjects with dyslipidemia who also have prediabetes * the age between 35 and 70 years old exclusion criteria: * intake of any medicine that affect lipid and glucose metabolism currently or in the preceding 6 months * dietary supplementation with phytochemicals including anthocyanins in the preceding 2 months * history of acute or chronic infectious disease, autoimmune disease, cancer, traumatic injury, or surgery in the preceding 1 month * history of severe chronic disease including as and cvd, liver or renal dysfunction, and lactation or pregnancy * pregnant woman and breast feeding women

Keywords: anthocyanins dyslipidemias dose response
efficacy of re-treatment with cimzia® in subject with chronic plaque psoriasis

Conditions: Psoriasis

Summary: the primary objective is to assess differences in pasi scores between week 12 of study c87040 \[nct00245765\] and week 12 of re-treatment in this study.


Eligibility criteria:
inclusion criteria: * subject having responded to treatment at week 12 in study c87040 and having relapsed during the follow-up period * female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of cdp870 exclusion criteria: * subjects with erythrodermic, guttate, generalized pustular form of psoriasis * any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough) * positive hepatitis b surface antigen test and /or hepatitis c antibody test results * positive human immunodeficiency virus (hiv) test result * white blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter * suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis) * systemic lupus erythematosus * participation in a clinical study within the past 3 months except study c87040 * any other condition, which in the investigator's judgment would make the subject unsuitable for inclusion in the study

Keywords: moderate to severe chronic plaque psoriasis anti tnf α cdp 870 cimzia® certolizumab pegol retreatment
a pilot study of rituximab for the anticoagulation resistant manifestations of antiphospholipid syndrome

Conditions: Antiphospholipid Syndrome

Summary: rituximab antiphospholipid syndrome (ritaps) study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (apl) -related certain clinical problems.

persistently antiphospholipid antibody (apl)-positive patients, age 18 - 75 years of age, with anticoagulation-resistant manifestations of aps and fulfilling protocol defined study inclusion criteria will receive two doses of rituximab, and will be followed for 6 and 12 months for clinical and safety outcomes, respectively. patients are eligible to take part in this study if their blood test is persistently positive for apl and they have one or more of the apl-related clinical problem(s) listed below: low platelet (blood cells involved in the prevention of bleeding) count; anemia (deficiency of red blood cells); heart valve disease; skin ulcers; kidney smal vessel blood clots; and/or memory problems.

Eligibility criteria:
inclusion criteria: * - positive apl profile defined as: * positive lupus anticoagulant test as defined by the international society on thrombosis and haemostasis, on two or more occasions, at least 12 weeks apart and/or * positive anticardiolipin antibody (acl) immunoglobulin g(ig)g/m/a isotype, present in \> 40u, on two or more occasions, at least 12 weeks apart and/or * positive anti-β2-glycoprotein-i (aβ2gpi) igg/m/a isotype, present in \> 40u, on two or more occasions, at least 12 weeks apart and - clinical features attributable to apl that are resistant to warfarin and/or heparin: * persistent thrombocytopenia and/or * persistent autoimmune hemolytic anemia and/or * cardiac valve disease and/or * chronic skin ulcers and/or * renal thrombotic microangiopathy and/or * cognitive dysfunction with/without white matter changes exclusion criteria (selected): * \> 4/11 american college of rheumatology classification criteria for sle * acute thrombosis * history of stroke (only for patients with cognitive dysfunction) * positive hepatitis b or c serology * history of positive hiv * acute or chronic pancreatitis * treatment with any investigational agent within 4 weeks of screening * receipt of a live vaccine within 4 weeks prior to randomization * previous treatment with rituximab (mabthera® / rituxan®) * previous treatment with natalizumab (tysabri®) * known active bacterial, viral fungal mycobacterial, or other infection * pregnancy * concomitant malignancies or previous malignancies, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * history of psychiatric disorder that would interfere with normal participation in this protocol * significant cardiac or pulmonary disease

Keywords: antiphospholipid syndrome
dietary approaches for cardiometabolic health

Conditions: Obesity, Abdominal; Dyslipidemias; Insulin Resistance; Blood Pressure; Weight Loss

Summary: this pilot study aims to recruit 30 adults with abdominal obesity, without major chronic disease, and test whether clinical dietary advice that is solely focused on the timing of eating (time restricted eating), has an effect on cardiometabolic health compared to standard dietary advice for cardiometabolic health, which is focused on content. the goal of this pilot study is to develop and hone dietary counseling approaches for time restricted eating for rd's in a clinical practice paradigm, and collect data on testing this intervention compared to standard dietary counseling approaches for cardiometabolic health.


Eligibility criteria:
inclusion criteria: * abdominal obesity (waist circumference ≥35" for women and ≥40" for men; if asian ethnicity, ≥35" for men and ≥31.5" for women) * weight stable over the previous 2 months * medications stable for \> 3 months * self-reported 24-hr sleep-wake patterns within the appropriate range as defined by the national sleep foundation (self-reported habitual sleep duration 6-10 hours during nocturnal hours) * regular meal patterns * from the greater uci and orange county area * willing to incorporate a dietary approach aimed at improving cardiometabolic health and weight management * able to speak, read and understand english or spanish exclusion criteria: * self-reported unstable hypertension * type 1 or 2 diabetes mellitus * heart, renal, or liver disease * cancer or active neoplasms * hyperthyroidism unless treated and under control * taking any medications known to affect clinical risk measures of interest or weight/energy expenditure (except for stable blood pressure medication) * active usual smoking (tobacco or marijuana) * alcohol intake \> 3 drinks/day * pregnancy, current lactation, or plans to become pregnant during the study